Key points are not available for this paper at this time.
Tumor burden influences prognosis in lymphoma, with unidimensional bulk used for risk assessment and decisions about radiotherapy consolidation (11). Total metabolic tumor volume (TMTV) using 18F-FDG PET emerged 10 y ago as a promising biomarker (22) that was superior to bulk (33).
Barrington et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: